Diagnosing breast cancer using Raman spectroscopy: prospective analysis
Name
Feld_Diagnosing breast cancer.PDF
Size
249.73 KB
Format
Adobe PDF
Checksum (MD5)
966310c20d4571b48fae740401ca3c32
Author(s)
Haka, Abigail S.
Gardecki, Joseph A.
Nazemi, Jonathan H.
Volynskaya, Zoya I.
Shenk, Robert
Wang, Nancy
Dasari, Ramachandra Rao
Fitzmaurice, Maryann
Feld, Michael S.
Date Issued
October 2009
Journal
Journal of Biomedical Optics
Publisher
Society of Photo-Optical Instrumentation Engineers
Citation
Haka, Abigail S. et al. “Diagnosing breast cancer using Raman spectroscopy: prospective analysis.” Journal of Biomedical Optics 14.5 (2009): 054023-8.
Version
Final published version
Abstract
Abigail S. Haka, Zoya Volynskaya, Joseph A. Gardecki, and Jon Nazemi
Massachusetts Institute of Technology, George R. Harrison Spectroscopy Laboratory, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139
Robert Shenk and Nancy Wang
University Hospitals Case Medical Center and Case Western Reserve, 11100 Euclid Avenue, Cleveland Ohio 44106
Ramachandra R. Dasari
Massachusetts Institute of Technology, George R. Harrison Spectroscopy Laboratory, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139
Maryann Fitzmaurice
University Hospitals Case Medical Center and Case Western Reserve, 11100 Euclid Avenue, Cleveland Ohio 44106
Michael S. Feld
Massachusetts Institute of Technology, George R. Harrison Spectroscopy Laboratory, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139
We present the first prospective test of Raman spectroscopy in diagnosing normal, benign, and malignant human breast tissues. Prospective testing of spectral diagnostic algorithms allows clinicians to accurately assess the diagnostic information contained in, and any bias of, the spectroscopic measurement. In previous work, we developed an accurate, internally validated algorithm for breast cancer diagnosis based on analysis of Raman spectra acquired from fresh-frozen in vitro tissue samples. We currently evaluate the performance of this algorithm prospectively on a large ex vivo clinical data set that closely mimics the in vivo environment. Spectroscopic data were collected from freshly excised surgical specimens, and 129 tissue sites from 21 patients were examined. Prospective application of the algorithm to the clinical data set resulted in a sensitivity of 83%, a specificity of 93%, a positive predictive value of 36%, and a negative predictive value of 99% for distinguishing cancerous from normal and benign tissues. The performance of the algorithm in different patient populations is discussed. Sources of bias in the in vitro calibration and ex vivo prospective data sets, including disease prevalence and disease spectrum, are examined and analytical methods for comparison provided.
MIT Department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Massachusetts Institute of Technology. Department of Physics
Massachusetts Institute of Technology. Spectroscopy Laboratory
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
http://dx.doi.org/10.1117/1.3247154
